Equibles does not estimate personal net worth.
Get an email with a short summary when Roivant Sciences Ltd. publishes a filing, an earnings call transcript or a press release.
Get ROIV alertsRichard Pulik is recorded as CFO at Roivant Sciences Ltd. (ROIV). The newest filing on record that lists Richard Pulik as CFO at Roivant Sciences Ltd. (ROIV) is dated July 29, 2026. The proxy statement of Roivant Sciences Ltd. reports total compensation of $4,190,602 for Richard Pulik in fiscal 2025, including a base salary of $450,883. Disclosed compensation is on record for 3 fiscal years. Richard Pulik has spoken on 2 earnings calls across 1 company, most recently for Roivant Sciences Ltd. on February 1, 2023. Roivant Sciences Ltd. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Roivant Sciences Ltd. includes Eric Venker (CEO and COO), Matthew Gline (CEO and Board Member), Jennifer Humes (Chief Accounting Officer) and 7 others.
“Obviously, once AD approval comes through on VTAMA towards the end of the year, we would ramp up the sales efforts there, so you'd see an uptick as we approach that towards the end of the year.”
“We haven’t provided any guidance at this point, and we expect to initiate at least four Phase 2/3 studies in 2022 depending on FDA feedback.”
Start not stated–present
Last confirmed July 29, 2026
Biotechnology · Healthcare
CFO
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Roivant Sciences Ltd. (ROIV) | Chief Financial Officer | $450,883 | $4,190,602 |
| 2024 | Roivant Sciences Ltd. (ROIV) | Chief Financial Officer | $437,750 | $4,127,151 |
| 2023 | Roivant Sciences Ltd. (ROIV) | Chief Financial Officer | $425,000 | $5,149,434 |
